Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA) Files An 8-K Other Events

Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA) Files An 8-K Other Events
Item 8.01. Other Events.

Story continues below

On December6, 2018, Momenta Pharmaceuticals,Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs& Co. LLC (the “Underwriter”), in connection with the public offering, issuance and sale by the Company of 17,391,305 shares of the Company’s common stock, par value $0.0001 per share, at a public offering price of $11.50 per share, less underwriting discounts and commissions, to an effective registration statement on FormS-3 (File No.333-209813) and a related prospectus supplement filed with the Securities and Exchange Commission. Under the terms of the Underwriting Agreement, the Company has also granted the Underwriter an option exercisable for 30 days to purchase up to an additional 2,608,695 shares of its common stock at the public offering price, less underwriting discounts and commissions.

The Company expects to receive net proceeds from the offering of approximately $189.1 million, or approximately $217.5 million if the Underwriter exercises its option to purchase additional shares in full, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds of the offering for the development of its pipeline of product candidates and for general corporate purposes, including working capital.

The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions.

The above description of the Underwriting Agreement is qualified in its entirety by reference to the full text of the Underwriting Agreement, a copy of which is filed as Exhibit1.1 hereto and is incorporated herein by reference.

Latham& Watkins LLP, counsel to the Company, has issued an opinion to the Company, dated December7, 2018, regarding the validity of the shares of common stock to be issued and sold in the offering. A copy of the opinion is filed as Exhibit5.1 to this Current Report on Form8-K.

Item 9.01 Financial Statements and Exhibits.


EX-1.1 2 a18-41151_4ex1d1.htm EX-1.1 Exhibit 1.1   Execution Version Momenta Pharmaceuticals,…
To view the full exhibit click here

About Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA)

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.

An ad to help with our costs